Parents often want to know how long asthma will persist in their children. In a longitudinal, population based study from New Zealand, children were enrolled shortly after birth, and they or their parents were surveyed about respiratory events from ages 9 to 26 years. Subjects were also tested for atopy, hyperresponsiveness to methacholine, and responsiveness to bronchodilators at various times.
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Of 613 subjects who responded to all surveys, 51.4% had reported wheezing on at least two surveys by age 26. By age 26, 14.5% had asthma persisting from onset; of the rest, 27.4% reported never wheezing; 21.2% had transient wheezing (reported once); 15% were wheeze free at age 26; 12.4% had relapsed (wheezing had stopped and recurred); and 9.5% had intermittent wheeze (reported at some assessments). Of the 168 who reported remission, 45.2% relapsed by age 26. Persistence of wheeze was significantly related to positive skin test for dust mites at age 13, female sex, smoking at age 21, and airway hyperresponsiveness. Airway hyperresponsiveness, dust-mite allergen sensitivity, and young age were significantly related to relapse.
Comment:
The good news: Many children who wheeze stop by the time they become young adults. The bad news: About 15% of children will wheeze for their entire lives, and about half of those who stop wheezing during childhood relapse by early adulthood. Results of other studies indicated that children of asthmatic parents are more likely to wheeze as they get older. A family history of asthma, early age at onset, and a history of atopy are all predictors of adult wheezing.
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Nebulized Therapy Not Useful For Bronchiolitis
The treatment for bronchiolitis in infants is controversial. Therapies such as racemic epinephrine and nebulized albuterol (salbutamol) improve outcomes within the first few hours of use, but their longer-term efficacy is questionable. These Canadian researchers found epinephrine and (salbutamol) albuterol to be no more effective than placebo during several days of use.
They studied 149 infants younger than 12 months who had diagnoses of bronchiolitis requiring hospitalization and who had no previous history of wheezing or bronchodilator use. Infants were randomized to receive epinephrine, albuterol (salbutamol), or placebo by nebulization every 1 to 6 hours. Outcome was assessed in a blinded manner.
There were no significant differences among groups in a primary outcome, mean length of hospital stay (about 2.5 days in all groups). Secondary outcomes -time to normal oxygenation, respiratory distress, adequate oral intake of fluids, and time to infrequent nebulizations (every 4 hours or less) -were also comparable among the groups.
Comment:
It is possible that children older than 12 months would have responded to epinephrine or albuterol (salbutamol). Unfortunately, corticosteroids, also often used to treat bronchiolitis, were not evaluated. Oxygen and supportive care should be the mainstays of treatment. However, as I have seen many children respond dramatically to nebulization therapy, I will continue to give epinephrine or (salbutamol) albuterol as a therapeutic trial, but I will maintain that medication only if it appears to benefit the child.
